

# 2021 Mayo Clinic and the Society for Neuro Oncology Online CME Course (Recorded March-May 2021)

## **Activity Description**

This comprehensive online review of critical neuro-oncology topics will address most frequently encountered clinical challenges, such as: management of primary and metastatic CNS tumors, pathology and classification, neuro-surgery, radiation therapy, chemotherapy, imaging, pediatric brain cancer, brain and spine metastases, management of neurological complications, and palliative care. Participants will benefit from presentations by faculty representing the top national neuro-oncology centers across the country. After completing both modules, they will find this course to be an excellent resource in preparing for the neuro-oncology board exam.

## **Target Audience**

Neuro-oncology physicians (MD/DO), physician assistants, nurse practitioners, registered nurses, fellows, residents, medical students, social workers, and industry contacts.

## **Learning Objectives**

Upon completion of this activity you will be able to:

- Recognize the most common diagnostic entities in neuro-oncology
- Explain available treatment options for primary and secondary brain tumors
- Identify the types of radiotherapy used in neuro-oncology and describe associated adverse effects
- Apply management techniques for neurologic complications of cancer
- Explain which chemotherapies are used in the treatment of brain cancer and related side effects
- Recognize the most common medical complications in patients with brain cancer
- Identify the most common diagnostic entities in pediatric neuro-oncology
- Explain available treatment options for pediatric brain tumors

Utilization of this Mayo Clinic online (enduring materials) course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be in this course. Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.

## **Accreditation Statement**



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## **Credit Statement(s)**

### **AMA**

The Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 9.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Disclosure Summary**

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

### **Financial relationship(s):**

| <b>Name</b>                       | <b>Nature of Relationship</b> | <b>Company</b>  |
|-----------------------------------|-------------------------------|---|
| David M. Peereboom, M.D., FACP    | Consultant                    | Sumitomo Dainippon Pharma Oncology, Orbus Therapeutics  |
|                                   | Grant/Research Support        | Bristol Myers-Squibb, Genentech/Roche, Mylan, Neonc Technologies, Novartis, Orbus Therapeutics, Pfizer, Stemline Therapeutics |
| Katherine B. Peters, M.D., Ph.D.  | Consultant                    | Agios, Bayer  |
|                                   | Grant/Research Support        | Abbvie, Agios, Biomimetix, Novocure   |
| Helen A. Shih, M.D., M.S., M.P.H. | Honoraria                     | UpToDate  |

### **No Financial relationship(s):**

#### **Name**

|                                |  |
|--------------------------------|--|
| Adrienne A. Boire, M.D., Ph.D. | Maciej Mrugala, M.D., Ph.D., M.P.H., F.A.A.N |
| Peter D. Canoll, M.D., Ph.D.   | Cristina Valencia Sanchez, M.D., Ph.D.       |
| Erin M. Dunbar, M.D.           | Gelareh Zadeh, M.D. Ph.D.                    |
| J. Charles Haynes, J.D.        |  |

Reference to off-label usage(s) of pharmaceuticals or instruments in their presentation:

---

|                                |  |
|--------------------------------|--|
| Rimas V. Lukas, M.D.           | SMO inhibitors, Akt inhibitors for meningioma. BRAF and MEK inhibition for BRAF mutated tumors. HIF2 alpha inhibition for hemang |
| Sonia Partap, M.D., M.S.       | Various chemotherapies   |
| David M. Peereboom, M.D., FACP | 35+multiple Pharmaceutical agents, many generic  |

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to [review disclosures](#).

**Mayo Clinic Disclaimer**

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

**Prerequisites for Participation**

There are no prerequisites needed prior to participating in this education activity.

**How to Obtain Credit**

Watch the videos, complete the evaluations and quizzes, and submit for credit.

**Method of Participation**

Participation in this activity consists of reviewing the online course and completing the post-test.

**Release and Expiration Dates**

Release Date: May 27, 2021  
Expiration Date: November 6, 2022

**Faculty and Course Director Listing and Credentials**

**Course Director(s)**

Maciej Mrugala, M.D., Ph.D., M.P.H., F.A.A.N  
Mayo Clinic  
Phoenix, Arizona

Katherine B. Peters, M.D., Ph.D.  
Duke Cancer Center  
Durham, North Carolina

**Additional Planning Committee Members**

J. Charles Haynes, J.D.  
Society for Neuro-Oncology  
Austin, Texas

Gelareh Zadeh, M.D. Ph.D.  
Society for Neuro-Oncology  
Austin, Texas

**Faculty:**

---

Adrienne A. Boire, M.D.,  
Ph.D.  
Memorial Sloan Kettering  
Cancer Center  
New York, New York

Peter D. Canoll, M.D.,  
Ph.D.  
Columbia University Irving  
Medical Center  
New York, New York

Erin M. Dunbar, M.D.  
Piedmont Atlanta Hospital  
Atlanta, Georgia

Rimas V. Lukas, M.D.  
Northwestern Medicine,  
Feinberg School of  
Medicine  
Evanston, Illinois

Sonia Partap, M.D., M.S.  
Stanford University & Lucile Packard  
Children's Hospital  
Palo Alto, California

David M. Peereboom, M.D., FACP  
Cleveland Clinic Lerner College of  
Medicine  
Cleveland, Ohio

Helen A. Shih, M.D., M.S., M.P.H.  
Harvard Medical School  
Boston, Massachusetts.

Cristina Valencia Sanchez, M.D.,  
Ph.D.  
Mayo Clinic  
Scottsdale, Arizona

**Copyright**

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2021